Akorn Offloads Consumer Health For $230m

All-Cash Deal Allows Beleaguered Firm To Invest In Optimizing Prescription Business

Akorn has announced a $230m all-cash deal to divest its consumer healthcare business to Prestige Consumer Healthcare. The transaction will allow Akorn – which recently went through bankruptcy proceedings – to invest in optimizing its prescription business.

Akorn website magnifying glass
Akorn has struck a $230m deal for its consumer healthcare business • Source: Alamy

Akorn has struck a deal to divest its consumer healthcare business to Prestige Consumer Healthcare for $230m in cash. The company said the transaction – which is expected to close in the third quarter of 2021 – would allow it to invest in optimizing its prescription business.

Earlier this year, the company had revealed that after exiting Chapter 11 bankruptcy protection – following a sale to its...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains